Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Abstract: A communication bus (B1, B2, Bp) in a motor vehicle (110) transfers electrical signals between the nodes (N1, N2, N3, Nn, N21, N2m, Np1, Npr) included in the motor vehicle. The communication bus comprises two unshielded signal lines (S1, S2) and a decoupling line (D), which are configured so as to divert undesired electromagnetic radiation deriving both from external systems that are not connected to the communication bus (B1, B2, Bp) and the electrical signals transferred via the unshielded signal lines (S1, S2). The decoupling line (D) is connected for alternating current to a ground potential in one and only one (N3) of the nodes (N1, N2, N3, Nn, N21, N2m, Np1, Npr) included in the communication system.

Abstract: A method of distributing a plurality of media content services (S1-S5) across a distribution network comprising dividing each of the plurality of media content services (S1-S5) into segments and transmitting the segments of each of the plurality of media content services as a sequence of bursts (305), wherein there is a window period (303) between successive bursts (305) during which media content is not transmitted. Each of the media content services (S1-S5) has a respective bit rate and the transmitting comprises transmitting each of the segments at a higher bit rate to create the window periods (303) between successive bursts (305). Starts of bursts (305) of the plurality of media content services (S1-S5) are staggered in time with respect to one another. At least one of the media content services (S1-S5) can comprise a plurality of media content service representations of different bit rate. The media content services and media content service representations can be transmitted as multicasts.

Abstract: An object with embodiments of the present invention is to achieve a solution for fast channel change that improves bandwidth utilization, wherein the fast channel change is accomplished by initiating a unicast stream until a multicast stream can provide the desired media. The bandwidth utilization is achieved by delaying the multicast session and by terminating the unicast session at the latest when the multicast session starts. The delay of the multicast session is dependent on the network latency. Latency in this context refers to the time passed from when the client sends an IGMP JOIN message until it receives the first packet of the multicast stream.

Abstract: An object with embodiments of the present invention is to achieve a solution for fast channel change that improves bandwidth utilization, wherein the fast channel change is accomplished by initiating a unicast stream until a multicast stream can provide the desired media. The bandwidth utilization is achieved by delaying the multicast session and by terminating the unicast session at the latest when the multicast session starts. The delay of the multicast session is dependent on the network latency. Latency in this context refers to the time passed from when the client sends an IGMP JOIN message until it receives the first packet of the multicast stream.

Abstract: A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Abstract: There is provided pharmaceutical compositions for the treatment of migraine comprising a pharmacologically-effective amount of a triptan or an ergot, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles.

Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles.

Abstract: There is provided pharmaceutical compositions that are useful for inter alia the treatment of motor fluctuations in patients receiving L-dopa for the treatment of Parkinson's disease comprising a weakly acidic material and a pharmacologically-effective amount of L-dopa, presented in particulate form upon the surfaces of larger carrier particles.

Abstract: A method of detecting inflammatory processes comprises (a) administering per-orally or per-rectally a composition comprising a diagnostically effective amount of L-[guanido-15N2]-arginine, L-[guanido-15N]-arginine, their mixtures and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; (b) collecting a sample of exhaled air, saliva or urine; (c) determining 15NO in the air sample or its transformation products 15N-nitrite and/or 15N-nitrate in the saliva sample or urine. Also disclosed is a corresponding diagnostic composition for use in diagnosing inflammatory processes and a method for its manufacture.

Abstract: A method of detecting inflammatory processes comprises (a) administering per-orally or per-rectally a composition comprising a diagnostically effective amount of L-[guanido-15N2]-arginine, L-[guanido-15N]-arginine, their mixtures and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; (b) collecting a sample of exhaled air, saliva or urine; (c) determining 13NO in the air sample or its transformation products 15IN-nitrite and/or 15N-nitrate in the saliva sample or urine. Also disclosed is a corresponding diagnostic composition for use in diagnosing inflammatory processes and a method for its manufacture.

Abstract: A preparation for administering isotope-labelled urea together with acid in a solid form that is influenced by activity of Helicobacter pylori in the stomach only, avoiding any non-Helicobacter (unspecific) urease activity in the oral cavity and the pharynx. The preparation dissolves very quickly in the stomach. The preparation is used to show increased urease activity in the stomach in association with an ongoing Helicobacter pylori infection.